Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing a…
What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…
What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…
Methicillin-resistant Staphylococcus aureus (MRSA) is an important causative pathogen of a range of hospital-treated infections. The steadily increasing severity of infections caused by MRSA that…
Last Updated 9 December 2013 The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. More patients…